Role of PANoptosis in cancer: Double-edged sword effects and targeted therapies
International Immunopharmacology · 2026-07 · 181 · 116702
DOI: 10.1016/j.intimp.2026.116702 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-07. Verfasst von Bai-Yu Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, School of Stomatology, Henan University, Kaife…. Hauptthemen laut MEDLINE: Neoplasms, Necroptosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 129 Literaturangaben. Gefördert von: Henan University, National Natural Science Foundation of China, Henan Provincial Science and Technology Research Project.
Abstract (Originalsprache)
PANoptosis is a recently recognized inflammatory form of programmed cell death mediated by the cytoplasmic multiprotein complex termed the PANoptosome, which integrates pyroptosis, apoptosis, and necroptosis. In cancer, PANoptosis exhibits a marked double-edged sword nature. On the one hand, its chronic or dysregulated activation may promote tumor progression by sustaining inflammation, shaping an immunosuppressive microenvironment, and facilitating invasion and metastasis. On the other hand, robust induction of PANoptosis can suppress tumor growth by triggering immunogenic cell death, overcoming apoptotic resistance, and sensitizing tumors to chemotherapy, radiotherapy, and immunotherapy. Importantly, these opposing effects are not fixed properties of PANoptosis, but are jointly determined by signal strength, molecular activation patterns, tumor stage, and tumor heterogeneity. This review summarizes the molecular mechanisms of PANoptosis and its dual roles in cancer, with particular emphasis on therapeutic strategies targeting PANoptosis. Major translational challenges are also highlighted, including the predominance of preclinical evidence, the lack of robust biomarkers, and the risk of inflammation-related toxicity, all of which underscore the need for more precise and context-dependent regulation of PANoptosis in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, School of Stomatology, Henan University, Kaifeng, Henan 475004, China; Department of Stomatology, Huaihe Hospital of…
Förderung
- Henan University
- National Natural Science Foundation of China
- Henan Provincial Science and Technology Research Project
Zitieren
APA
Chen, B. Y., Li, L., Wang, W. Q., Kong, Y., Wang, X., Liu, M. Y., Zhang, H. X., Zhou, Z., Li, H. J., & Wu, D. D. (2026). Role of PANoptosis in cancer: Double-edged sword effects and targeted therapies. International Immunopharmacology, 181, 116702. https://doi.org/10.1016/j.intimp.2026.116702
Vancouver
Chen BY, Li L, Wang WQ, Kong Y, Wang X, Liu MY, et al. Role of PANoptosis in cancer: Double-edged sword effects and targeted therapies. International Immunopharmacology. 2026;181:116702. doi:10.1016/j.intimp.2026.116702
BibTeX
@article{Chen2026,
author = {Chen, Bai-Yu and Li, Lu and Wang, Wen-Qing and Kong, Yan and Wang, Xi and Liu, Meng-Yao and Zhang, Han-Xi and Zhou, Zi and Li, Hong-Jie and Wu, Dong-Dong},
title = {Role of PANoptosis in cancer: Double-edged sword effects and targeted therapies},
journal = {International Immunopharmacology},
year = {2026},
volume = {181},
pages = {116702},
doi = {10.1016/j.intimp.2026.116702}
}
EUVIMED